All News

RA9003.jpg (keep)

Survival and Mortality in RA: time to move away from “one-size fits all”?

Aurelie Najm, MD, PhD

Patients with RA are known to have a higher mortality risk than the general population.

Read Article
lupus_0.jpg

Exciting Data for SLE: Plenaries from #ACR22

Michael Putman, MD, MSCI

ACR Convergence 2022 promises to be another exciting year for research in systemic lupus erythematosus (SLE), with multiple plenary sessions devoted to therapeutic advancements. Here’s a quick rundown of what to expect!

Read Article
question-mark-1872634_640.jpg

Do biologics help taper steroids in Adult Still’s Disease?

Bella Mehta, MBBS, MS

A Japanese large scale claims data study was able to collect 5-year data to study the treatment patterns in Still’s. In May 2019, intravenous tocilizumab was approved in Japan for Still’s disease. The study was designed to see patterns of steroid exposure before and after the approval of this therapy.

Read Article
pso.arm_.JPG

“Hey PRESTO!” – Early identification of psoriatic arthritis

Patricia Harkins, MD

Despite a wealth of treatment options, a number of notable unmet needs remain in PsA, most notably the significant diagnostic delay that many patients endure. We are all aware that those with psoriatic skin disease are the most at risk cohort for PsA. Identifying patients with psoriasis who have, or are at increased risk of PsA, appears to be the low hanging fruit that we just can’t fully seem to grasp.

Read Article
covid coronavirus virus

Long COVID and Rheumatic Disease

Akhil Sood, MD

The COVID-19 pandemic has had a significant impact worldwide particularly among those who are immunocompromised. Numerous studies have highlighted the increased risk of acute SARS-CoV-2 infection among patients with rheumatic diseases (RD).

Read Article
Best Overall! by Dr. Lauren Harper #ACR22 Image Competition @rheumnow https://t.co/D3bKJTx6ir
TheDaoIndex KDAO2011 ( View Tweet)
Keynote lecture from Abraham Varghese at #ACR22 @RheumNow Opening Session Physicians and Patients ◦ Physical examination is meaningful and cannot be replaced by technology ◦ Don’t treat the EHR, treat the patient ◦ Acknowledge how much goes into patient care by our nurses https://t.co/piV0O8O7Hw
Dr. Antoni Chan synovialjoints ( View Tweet)
#ACR22 Yr in Review. John Varga says novel vaccination immune therapy may reverse #fibrosis - at least in mice. Hope for #scleroderma & other fibrotic diseases. Data need to be transferred into human experiments @RheumNow https://t.co/ybFRXheQq3
Janet Pope Janetbirdope ( View Tweet)
Ab0344 #ACR22 CKD2+ a/w incr HCQ levels by 149 ng/mL vs CKD1 400 mg/d dose: incr HCQ levels by 448 ng/mL vs 200 Incr body wt by 15 kg -> decr HCQ levels by 82 ng/mL Social determinants didn't effect data >750ng/mL and >1000 predicted of 75% decr flare risk @Rheumnow #ACRBest https://t.co/p21rqnO4ym
Eric Dein ericdeinmd ( View Tweet)
New 2022 EULAR Recommendations for the Management of RA The updated '22 EULAR recommendations for the mgmt of RA were initially presented at EULAR '22, and are now in press delineating the most recent developments and perspectives in RA treatment. https://t.co/xnpOUnpgvy https://t.co/OWcRq7nZ57

Links:

Dr. John Cush RheumNow ( View Tweet)
We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/P41KybUuNw
Dr. John Cush RheumNow ( View Tweet)
Inspiring words from Dr. @cuttingforstone, "For these times, we must heed the call to adventure, find the tools & weapons never thought of before, have courage, have faith, tell our story, find our epiphanies bec this too shall pass..." #ACR22 @RheumNow #RheumTwitter https://t.co/l3DPnIBxq6
sheila RHEUMarampa ( View Tweet)
“The Stone Age did not end because we ran out of stones, it's because we found better technology.” – Dr. A. Verghese on how we need to be smarter about the practice medicine to accomplish more without being bogged down by logistics. #scribes @cuttingforstone @rheumnow #ACR22 https://t.co/20fP8cRRrv
TheDaoIndex KDAO2011 ( View Tweet)
Dr. Olga Petryna is back for her 8th year as a RheumNow reporter. Follow her @DrPetryna for real-time #ACR22 coverage. https://t.co/zwCt46uqQj
Dr. John Cush RheumNow ( View Tweet)
Introducing RheumNow #ACR22 reporter, Dr. Catherine Sims! She'll will be joining us and reporting on SpA and reproductive health. Follow @DrCassySims for real-time ACR coverage this weekend! https://t.co/LU39uYs6WM
Dr. John Cush RheumNow ( View Tweet)
Which one to use for prevention and which for treatment? Drugs covered by #Medicare based on indication #osteoporosis #acr22 #acrreview ⁦@RheumNow⁩ https://t.co/KE5F6Sn3wg
TheDaoIndex KDAO2011 ( View Tweet)
What's the role of MRI in #osteoarthritis? #ACR22 @RheumNow #acrreview https://t.co/uZEzUSLo88
sheila RHEUMarampa ( View Tweet)
When referring to radiographs in #osteoarthritis, it can be better described as early, advanced or end-stage as it only shows the extent of joint damage accrued over time, not telling us much on the severity of disease - Dr. Scanzello #ACR22 @RheumNow https://t.co/m7Vdmu6KM6
sheila RHEUMarampa ( View Tweet)
#osteoporosis baseline lab work should be completed to assess for secondary causes. DEXA is underutilized in men and should be considered especially in men with inflammatory disease Baseline labs: CBC, BMP, PTH, vit D, TSH, urine ca, testosterone #ACR22 @RheumNow https://t.co/byXLQFpe3n
Catherine Sims, MD DrCassySims ( View Tweet)
2019 Reccs for #OA RX- educate, exercise and weight mgmt is cornerstone . Hyaluronic acid supplementation and stem cell, PRP injx not recc. #acr22 ⁦#acrreview⁩ @rheumnow https://t.co/v5w84z9eCu
TheDaoIndex KDAO2011 ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×